Sarepta Therapeutics
SRPT
#1354
Rank
$11.01 B
Marketcap
$118.08
Share price
-1.97%
Change (1 day)
22.86%
Change (1 year)
Sarepta Therapeutics is an American medical research company dedicated to the discovery and development of precisely effective gene therapeutics for the treatment of rare neuromuscular diseases.

P/E ratio for Sarepta Therapeutics (SRPT)

P/E ratio as of October 2023 (TTM): -11.7

According to Sarepta Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -11.6828. At the end of 2018 the company had a P/E ratio of -20.1.

P/E ratio history for Sarepta Therapeutics from 2001 to 2022

PE ratio at the end of each year

Year P/E ratio Change
2018-20.1-72.14%
2017-72.31338.35%
2016-5.02-32.42%
2015-7.4374.15%
2014-4.27-28.96%
2013-6.01

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
16.7-242.86%๐Ÿ‡บ๐Ÿ‡ธ USA
-2.43-79.23%๐Ÿ‡บ๐Ÿ‡ธ USA
-1.07-90.87%๐Ÿ‡บ๐Ÿ‡ธ USA
-20.1 71.90%๐Ÿ‡บ๐Ÿ‡ธ USA
-4.63-60.35%๐Ÿ‡บ๐Ÿ‡ธ USA
-4.98-57.40%๐Ÿ‡บ๐Ÿ‡ธ USA
-2.02-82.74%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.